It is unclear why high body mass index (BMI) is associated with a lower risk of death
in patients with cardiovascular disease (CVD). We hypothesized that the impact of
higher BMI varies by the patient’s baseline risk of death. We analyzed data from 14
prospective studies conducted by us in 50 countries of 170,470 patients: 22.8% without
CVD, 29.4% with stable CVD and 47.8% with acute coronary syndromes (ACS). Compared
with overweight (BMI 25 to 29.9 kg/m2), normal weight (BMI 20 to 24.9 kg/m2), and underweight (BMI < 20 kg/m2) were associated with higher mortality in all cohorts. Compared with overweight,
the risk of death among those with obesity (BMI ≥ 30 kg/m2) varied depending on the population studied: HR (95% confidence interval) in those
without CVD, with stable CVD, and with ACS were 1.20 (1.01 to 1.45; p = 0.04), 1.08
(1.02 to 1.15; p = 0.01), and 1.01 (0.93 to 1.10; p = 0.72), respectively. The BMI
associated with lowest mortality increased as cohort risk increased (no-CVD 27.2 kg/m2, stable CVD 28.1 kg/m2, and ACS 30.9 kg/m2; p <0.001). Within each cohort, the optimal BMI value was higher in the high-risk
subgroup. In the ACS cohort, low-risk patients had an optimal BMI value of 29.1 kg/m2 while in the high-risk group higher BMI was associated with lower risk of death (interaction-p
<0.001). In conclusion, between and within cohorts of people without CVD, stable CVD,
and ACS, higher BMI was associated with lower risk of death in higher risk groups.
The benefits of increased body fat (i.e., increased caloric reserve) may counteract
the hazards in high-risk groups, suggesting an alternative explanation of the obesity
paradox.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004.J Am Coll Surg. 2008; 207: 928-934
- Body-mass index and mortality among 1.46 million white adults.N Engl J Med. 2010; 363: 2211-2219
- Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents.Lancet. 2016; 388: 776-786
- AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.J Am Coll Cardiol. 2014; 63: 2985-3023
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).Eur Heart J. 2012; 33: 1635-1701
- Body mass index and mortality after acute coronary syndromes: a systematic review and meta-analysis.Acta Cardiol. 2017; : 1-7
- Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies.Lancet. 2006; 368: 666-678
- Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis.Heart. 2015; 101: 1631-1638
- Effect of body mass index on clinical events after acute coronary syndromes.Am J Cardiol. 2017; 120: 1453-1459
- Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.N Engl J Med. 2013; 369: 145-154
- Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study.Atherosclerosis. 2012; 220: 587-592
- Why cachexia kills: examining the causality of poor outcomes in wasting conditions.J Cachexia Sarcopenia Muscle. 2013; 4: 89-94
- Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.N Engl J Med. 2000; 342: 145-153
- Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N Engl J Med. 2001; 345: 494-502
- Comparison of fondaparinux and enoxaparin in acute coronary syndromes.N Engl J Med. 2006; 354: 1464-1476
- Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.JAMA. 2006; 295: 1519-1530
- Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.Lancet. 2008; 372: 1174-1183
- Telmisartan, ramipril, or both in patients at high risk for vascular events.N Engl J Med. 2008; 358: 1547-1559
- Early versus delayed invasive intervention in acute coronary syndromes.N Engl J Med. 2009; 360: 2165-2175
- Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.Lancet. 2010; 376: 1233-1243
- Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.JAMA. 2010; 304: 1339-1349
- Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.Lancet. 2011; 377: 1409-1420
- Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study.Eur J Prev Cardiol. 2012; 19: 755-764
- Basal insulin and cardiovascular and other outcomes in dysglycemia.N Engl J Med. 2012; 367: 319-328
- Randomized trial of primary PCI with or without routine manual thrombectomy.N Engl J Med. 2015; 372: 1389-1398
- Blood-pressure and cholesterol lowering in persons without cardiovascular disease.N Engl J Med. 2016; 374: 2032-2043
- Indices of obesity derived from body weight and height.Br J Prev Soc Med. 1967; 21: 122-128
- Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).BMJ. 2006; 333: 1091
- Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo.Am J Physiol. 1999; 277: E971-E975
- The role of TNF in cardiovascular disease.Pharmacol Res. 1999; 40: 97-105
- The interaction of cardiorespiratory fitness with obesity and the obesity paradox in cardiovascular disease.Prog Cardiovasc Dis. 2017; 60: 30-44
Article info
Publication history
Published online: July 04, 2018
Accepted:
June 25,
2018
Received in revised form:
June 15,
2018
Received:
May 20,
2018
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
